<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>34(1)</volume><submitter>Nazzaro M</submitter><journal>Molecular Therapy Oncology</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936832</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression</pubmed_title><pmcid>PMC12936832</pmcid><pubmed_authors>Glaspell A</pubmed_authors><pubmed_authors>Elemento O</pubmed_authors><pubmed_authors>Behbehani G</pubmed_authors><pubmed_authors>Cripe T</pubmed_authors><pubmed_authors>Nazzaro M</pubmed_authors><pubmed_authors>Mardis E</pubmed_authors><pubmed_authors>Currier M</pubmed_authors><pubmed_authors>Canella A</pubmed_authors><pubmed_authors>Bhinder B</pubmed_authors><pubmed_authors>Rajappa P</pubmed_authors><pubmed_authors>Lee D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression</name><description/><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-16T21:55:20.651Z</modification><creation>2026-07-10T03:15:12.801Z</creation></dates><accession>S-EPMC12936832</accession><cross_references/></HashMap>